Gene therapy attack on Hard-to-Treat lymphoma shows early promise
NCT ID NCT07211048
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 20 times
Summary
This early study is testing a new gene therapy (LCAR02) for people with B-cell lymphoma that has returned or not responded to standard treatments. Up to 18 participants will receive the therapy to see if it is safe and can shrink or eliminate tumors. The goal is to gather initial information on side effects and how well the treatment works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Anhui Provincial Hospital
RECRUITINGHefei, Anhui, 230001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.